4.6 Article

Release of TGFβig-h3 by gastric myofibroblasts slows tumor growth and is decreased with cancer progression

期刊

CARCINOGENESIS
卷 33, 期 8, 页码 1553-1562

出版社

OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgs180

关键词

-

类别

资金

  1. National Institute of Health (TMEM) [5 U54 CA126513-04/1]
  2. North West Cancer Research Fund [CR793]
  3. Deutsche Krebshilfe

向作者/读者索取更多资源

Tumor progression has been linked to changes in the stromal environment. Myofibroblasts are stromal cells that are often increased in tumors but their contribution to cancer progression is not well understood. Here, we show that the secretomes of myofibroblasts derived from gastric cancers [cancer-associated myofibroblasts (CAMs)] differ in a functionally significant manner from those derived from adjacent tissue [adjacent tissue myofibroblasts (ATMs)]. CAMs showed increased rates of migration and proliferation compared with ATMs or normal tissue myofibroblasts (NTMs). Moreover, conditioned medium (CM) from CAMs significantly stimulated migration, invasion and proliferation of gastric cancer cells compared with CM from ATMs or NTMs. Proteomic analysis of myofibroblast secretomes revealed decreased abundance of the extracellular matrix (ECM) adaptor protein like transforming growth factor--induced gene-h3 (TGFig-h3) in CAMs, which was correlated with lymph node involvement and shorter survival. TGFig-h3 inhibited IGF-II-stimulated migration and proliferation of both cancer cells and myofibroblasts, and suppressed IGF-II activation of p42/44 MAPkinase; TGFig-h3 knockdown increased IGF-II- and CM-stimulated migration. Furthermore, administration of TGFig-h3 inhibited myofibroblast-stimulated growth of gastric cancer xenografts. We conclude that stromal cells exert inhibitory as well as stimulatory effects on tumor cells; TGFig-h3 is a stromal inhibitory factor that is decreased with progression of gastric cancers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据